An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy

Study Overview

This study is being done in subjects with advanced and/or metastatic solid tumors. The treatment-specific Module A portion of the study will test the combination of the investigational drugs BI 754091 and BI 754111.

  • IRB Number: 1904395200 (1381-0009)
  • Research Study Identifier: TX10498
  • Principal Investigator: Greg Durm, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.